O. Français-de-la-sclérose-en-plaques, (. R. , and S. V. , Fondation Rothschild, CHU de Marseille; Service de Neurologie (P.V.), CHU de Lille; Service de Neurologie (G.E.), CHU de Rennes; Service de Neurologie CHU de Dijon; Service de Neurologie CHU de Créteil; Service de Neurologie (P.L.), CHU de Montpellier; Service de Neurologie (L.M.), CHU de Limoges CHU de Caen; and INSERM UMR U1064 (D.A.L.), pp.21453-21457, 2002.

L. Kappos, E. Radue, O. Connor, and P. , A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis, New England Journal of Medicine, vol.362, issue.5, pp.387-401, 2010.
DOI : 10.1056/NEJMoa0909494

URL : https://hal.archives-ouvertes.fr/hal-00617764

J. Cohen, F. Barkhof, and G. Comi, Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis, New England Journal of Medicine, vol.362, issue.5, pp.402-415, 2010.
DOI : 10.1056/NEJMoa0907839

URL : https://hal.archives-ouvertes.fr/hal-00617750

P. Calabresi, E. Radue, and D. Goodin, Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial, The Lancet Neurology, vol.13, issue.6, pp.545-556, 2014.
DOI : 10.1016/S1474-4422(14)70049-3

C. Polman, O. Connor, P. Havrdova, and E. , A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis, New England Journal of Medicine, vol.354, issue.9, pp.899-910, 2006.
DOI : 10.1056/NEJMoa044397

D. Miller, D. Soon, and K. Fernando, MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS, Neurology, vol.68, issue.17, pp.1390-1401, 2007.
DOI : 10.1212/01.wnl.0000260064.77700.fd

B. Kleinschmidt-demasters and K. Tyler, Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis, New England Journal of Medicine, vol.353, issue.4, pp.369-374, 2005.
DOI : 10.1056/NEJMoa051782

A. Langer-gould, S. Atlas, and A. Green, Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab, New England Journal of Medicine, vol.353, issue.4, pp.375-381, 2005.
DOI : 10.1056/NEJMoa051847

S. Braune, M. Lang, and A. Bergmann, Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort, Journal of Neurology, vol.26, issue.30, pp.2981-2985, 2013.
DOI : 10.1007/s00415-013-7082-0

R. Carruthers, D. Rotstein, and B. Healy, An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy, Multiple Sclerosis Journal, vol.36, issue.10, pp.1381-1390, 2014.
DOI : 10.1177/1352458513477925

A. Gajofatto, M. Bianchi, L. Deotto, and M. Benedetti, Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis A Clinical Practice Observational Study, European Neurology, vol.72, issue.3-4, pp.173-180, 2014.
DOI : 10.1159/000361044

V. Jokubaitis, V. Li, and T. Kalincik, Fingolimod after natalizumab and the risk of short-term relapse, Neurology, vol.82, issue.14, pp.1204-1211, 2014.
DOI : 10.1212/WNL.0000000000000283

T. Kalincik, D. Horakova, and T. Spelman, Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis, Annals of Neurology, vol.82, issue.pt 12, pp.425-435, 2015.
DOI : 10.1002/ana.24339

S. Vukusic, Observatoire de la sclérose en plaques (OFSEP) Available at: http://www.ofsep.org/fr/la-cohorte, 2015.

C. Confavreux, O. Hommes, W. Mcdonald, and A. Thompson, EDMUS, a European database for multiple sclerosis., Journal of Neurology, Neurosurgery & Psychiatry, vol.55, issue.8, pp.671-676, 1992.
DOI : 10.1136/jnnp.55.8.671

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC489202

R. Haynes, Clinical Epidemiology: How to Do Clinical Practice Research, p.496, 2006.

R. Gross and K. Johnston, Levels of evidence: Taking Neurology(R) to the next level, Neurology, vol.72, issue.1, pp.8-10, 2009.
DOI : 10.1212/01.wnl.0000342200.58823.6a